Freenome

01/18/2023

For us, accessibility means meeting patients where they are. And it starts with our clinical studies. Thanks to great partners like Geisinger, The Sanderson Study will enable participation amongst urban and rural communities across Pennsylvania.

Learn more about our partnership:

– The Sanderson Study is Freenome’s clinical study that combines multiomics with real-world data to detect multiple cancers 

01/10/2023

Access to is fundamental in order to detect cancer in its earliest, most treatable stages. Find out how we are taking what we've learned during the pandemic to bring our tests to the forefront of clinical care in the latest FierceBiotech article.

https://www.fiercebiotech.com/medtech/jpm23-what-has-pandemic-done-us-freenome-and-other-diagnostics-developers-making-tests-more

If there’s one silver lining to the COVID-19 pandemic, it’s the amount of rapid innovation that occurred across medtech, biotech and healthcare to better serve patients who had either caught the co | In interviews with Fierce Medtech during the annual J.P. Morgan Healthcare Conference on Monday,...

01/04/2023

How do you build a company dedicated to the ambitious goal of ending cancer? According to Freenome co-founder Riley Ennis, it's not just about the science:

What drives a person to pursue such an ambitious goal as curing cancer? For Freenome Co-founder Riley Ennis , it was personal. “I watched my younger sister deal with a life-threatening medical condition and be saved,” he explained. Her treatment included experimental surgeries and cutting-edge m...

12/22/2022

As we head into 2023, Freenome CEO Mike Nolan shares with MedTech Dive how we are committed to overcoming our top competitor: cancer.
https://www.medtechdive.com/news/mike-nolan-freenome-ceo-colorectal-cancer-test/639404/

12/12/2022

By combining our expertise with partners like
Adc Therapeutics, we’re enabling the research necessary to help drive innovative therapies for those patients in need. Learn more:

– Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy

11/09/2022

We were honored to respond to The White House’s call to action to increase access to screening with Fight Colorectal Cancer and other industry leaders.
Learn more about the experience and what we’re doing together: https://www.freenome.com/blog-freenome/2022/10/26/freenome-joins-the-white-houses-cancer-moonshot-initiative

11/02/2022

Freenome takes a personal approach to its clinical study names, naming them in honor of employees’ loved ones who battled cancer–those who inspire us to achieve our mission for everyone's loved ones.
Learn the moving story behind The Vallania Study:
https://lnkd.in/gn4RBCx5

11/01/2022

Where you live shouldn’t matter when it comes to participating in breakthrough cancer research. Learn how more than 50 hospitals and community oncology practices have joined as partners in The Vallania Study so we can reach more patients across both urban and rural settings.

SOUTH SAN FRANCISCO, Nov. 1, 2022 — Freenome, a privately held biotech company, announced today 50 hospitals and community oncology practices across the United States have joined as clinical partners for its Vallania Study. The Vallania Study focuses on the detection of multiple cancers and launch...

10/26/2022

Freenome Co-Founder & Chief Product Officer Riley Ennis spoke at last week’s Oracle Cerner Corporation Health Conference on how we are working together to unite the healthcare ecosystem and provide new possibilities for patients.

Learn more about our partnership here: https://lnkd.in/gGzPMUm7

09/06/2022

Today we launch The Sanderson Study, our clinical study for multiple cancers that combines with real-world data. This study will build the infrastructure to bridge the gap between clinical research and clinical impact, and drive tailored insights for patient care.
freenome.com/freenome-launches-study-of-multiple-cancers-pairing-multiomics-with-real-world-data

08/11/2022

Diversity in clinical studies is critical to ensure our products are effective for all. That’s why it was critical that we made it easy for anyone, in any ZIP code, to participate in PREEMPT CRC, our clinical study for FDA approval of our blood test for (CRC).

Learn how we leveraged technology to help drive diversity from our Sr. Director of Clinical Development, Chuanbo Xu.

https://www.medicaldesignandoutsourcing.com/how-to-leverage-technology-to-drive-diversity-in-clinical-studies/

07/22/2022

We’re honored to head to The White House with Fight Colorectal Cancer and other industry leaders next week in response to President Joe Biden's call to action to increase access to screening.

Earlier this year, President Joe Biden announced plans to reignite the Cancer Moonshot with renewed leadership and new ambitious goals to “end cancer as we know it.” As part of …